Y-Mabs Therapeutics Inc (NASDAQ: YMAB) is -40.10% lower on its value in year-to-date trading and has touched a low of $3.86 and a high of $17.78 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The YMAB stock was last observed hovering at around $4.54 in the last trading session, with the day’s gains setting it 0.15%.
Currently trading at $4.69, the stock is -0.53% and -8.91% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.11 million and changing 3.30% at the moment leaves the stock -52.80% off its SMA200. YMAB registered -69.02% loss for a year compared to 6-month loss of -67.20%. The firm has a 50-day simple moving average (SMA 50) of $5.1488 and a 200-day simple moving average (SMA200) of $9.93625.
The stock witnessed a -4.29% gain in the last 1 month and extending the period to 3 months gives it a -24.11%, and is 7.82% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.38% over the week and 9.01% over the month.
Y-Mabs Therapeutics Inc (YMAB) has around 107 employees, a market worth around $212.07M and $87.69M in sales. Profit margin for the company is -33.83%. Distance from 52-week low is 21.50% and -73.62% from its 52-week high. The company has generated returns on investments over the last 12 months (-32.18%).
with sales reaching $19.97M over the same period.The EPS is expected to shrink by -43.15% this year, but quarterly earnings will post -4.74% year-over-year. Quarterly sales are estimated to grow 0.20% in year-over-year returns.
168.0 institutions hold shares in Y-Mabs Therapeutics Inc (YMAB), with institutional investors hold 82.41% of the company’s shares. The shares outstanding are 44.99M, and float is at 34.45M with Short Float at 10.62%. Institutions hold 72.26% of the Float.
The top institutional shareholder in the company is PARADIGM BIOCAPITAL ADVISORS LP with over 3.87 million shares valued at $46.76 million. The investor’s holdings represent 8.7923 of the YMAB Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 2.94 million shares valued at $35.5 million to account for 6.6755 of the shares outstanding. The other top investors are SOFINNOVA INVESTMENTS, INC. which holds 2.19 million shares representing 4.9845 and valued at over $26.51 million, while VANGUARD GROUP INC holds 4.4709 of the shares totaling 1.96 million with a market value of $23.64 million.
Y-Mabs Therapeutics Inc (YMAB) Insider Activity
The most recent transaction is an insider sale by Rossi Michael J, the company’s PRESIDENT & CEO. SEC filings show that Rossi Michael J sold 3,917 shares of the company’s common stock on Mar 07 ’25 at a price of $5.20 per share for a total of $20368.0. Following the sale, the insider now owns 0.14 million shares.
Y-Mabs Therapeutics Inc disclosed in a document filed with the SEC on Mar 07 ’25 that Gad Thomas (CHIEF BUSINESS OFFICER) sold a total of 10,810 shares of the company’s common stock. The trade occurred on Mar 07 ’25 and was made at $5.23 per share for $56536.0. Following the transaction, the insider now directly holds 0.2 million shares of the YMAB stock.
Still, SEC filings show that on Mar 07 ’25, Rajah Vignesh (Officer) Proposed Sale 4,946 shares at an average price of $5.20 for $25743.0. The insider now directly holds shares of Y-Mabs Therapeutics Inc (YMAB).
